Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (Q47547989)

3 February 2018

title

Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (English)

1 reference

3 February 2018

0 references

1

Lesley J Scott

1 reference

3 February 2018

publication date

29 January 2018

1 reference

3 February 2018

published in

Drugs

1 reference

3 February 2018

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

cites work

1 reference

12 December 2020

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

12 December 2020

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

12 December 2020

Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials

1 reference

12 December 2020

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

1 reference

12 December 2020

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

1 reference

12 December 2020

Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.

1 reference

12 December 2020

Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

1 reference

12 December 2020

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

1 reference

12 December 2020

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

1 reference

12 December 2020

Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy

1 reference

12 December 2020

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

1 reference

12 December 2020

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

1 reference

12 December 2020

The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study

1 reference

12 December 2020

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study

1 reference

12 December 2020

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

1 reference

12 December 2020

Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection

1 reference

12 December 2020

Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection

1 reference

12 December 2020

Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection

1 reference

12 December 2020

Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

1 reference

12 December 2020

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

1 reference

12 December 2020

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives

1 reference

12 December 2020

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study

1 reference

12 December 2020

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

1 reference

12 December 2020

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

1 reference

12 December 2020

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.

1 reference

12 December 2020

Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients

1 reference

12 December 2020

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.

1 reference

12 December 2020

Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies

1 reference

12 December 2020

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir

1 reference

12 December 2020

Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus

1 reference

12 December 2020

Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.

1 reference

12 December 2020

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

1 reference

12 December 2020

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

1 reference

12 December 2020

Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study

1 reference

12 December 2020

Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients

1 reference

12 December 2020

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

1 reference

12 December 2020

Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences

1 reference

12 December 2020

Reinventing HCV Treatment: Past and Future Perspectives

1 reference

12 December 2020

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study

1 reference

12 December 2020

Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.

1 reference

12 December 2020

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial

1 reference

12 December 2020

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir

1 reference

12 December 2020

Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

1 reference

12 December 2020

Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease

1 reference

12 December 2020

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection

1 reference

12 December 2020

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

1 reference

12 December 2020

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection

1 reference

12 December 2020

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.

1 reference

12 December 2020

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

1 reference

12 December 2020

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders

1 reference

12 December 2020

Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection

1 reference

12 December 2020

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study

1 reference

12 December 2020

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

1 reference

12 December 2020

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

1 reference

12 December 2020

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

1 reference

12 December 2020

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.

1 reference

12 December 2020

A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study

1 reference

12 December 2020

Treatment of Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.

1 reference

12 December 2020

1 reference

12 December 2020

A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects

1 reference

12 December 2020

Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients

1 reference

12 December 2020

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials

1 reference

12 December 2020

10.1007/S40265-018-0864-Z

Identifiers

DOI

1 reference

3 February 2018

release_ylg72swdt5enboyxzgijdo5yq4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ylg72swdt5enboyxzgijdo5yq4

24 November 2022

mapped directly with Wikidata item

1 reference

3 February 2018